3-FT: metabolite of FD-1; positional isomer of FTORAFUR [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 125110 |
| CHEMBL ID | 3272517 |
| SCHEMBL ID | 208416 |
| MeSH ID | M0084709 |
| Synonym |
|---|
| 3-(2-tetrahydrofuryl)-5-fluorouracil |
| 5-fluoro-3-(tetrahydro-2-furyl)uracil |
| uracil, 5-fluoro-3-(tetrahydro-2-furyl)- |
| 3-ft |
| 5-fluoro-3-(oxolan-2-yl)-1h-pyrimidine-2,4-dione |
| 63901-83-7 |
| 3-(tetrahydro-2-furanyl)-5-fluorouracil |
| 3-(tetrahydro-2-furanyl)-5-fluoro-2,4-pyrimidinedione |
| 5-fluoro-3-(tetrahydro-2-furyl)-uracil |
| SCHEMBL208416 |
| CHEMBL3272517 |
| tetrahydrofuranyl-5-fluorouracil |
| MGYWDJWGVICAEL-UHFFFAOYSA-N |
| 5-fluoro-3-tetrahydro-2-furanyl-2,4(1h,3h)-pyrimidinedione # |
| 5-fluoro-3-(tetrahydro-2-furanyl)uracil |
| DTXSID30980821 |
| 5-fluoro-2-hydroxy-3-(oxolan-2-yl)pyrimidin-4(3h)-one |
| 5-fluoro-3-(tetrahydrofuran-2-yl)pyrimidine-2,4(1h,3h)-dione |
| Excerpt | Reference | Relevance |
|---|---|---|
| "To prevent postoperative recurrence a randomized prospective trial was performed on 45 patients with bladder cancers by dividing them into 2 groups given either UFT therapy alone or UFT therapy in combination with Bestatin." | ( Adjuvant therapy with 5-fluoro-1-(2-tetrahydrofuryl)-2,4 (1H,3H)-pyrimidinedione (UFT) and Bestatin in patients with transitional cell carcinoma of the bladder--comparison between UFT therapy alone and UFT therapy in combination with Bestatin. Koshida, K; Kunimi, K; Uchibayashi, T; Yamamoto, H, 1995) | 0.29 |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1146942 | Antitumor activity against rat AH-130 cells allografted in Donryu rat assessed as tumor inhibition at 0.15 mmol/kg, po qd for 7 days measured on day 10 relative to control | 1978 | Journal of medicinal chemistry, Aug, Volume: 21, Issue:8 | Studies on antitumor agents, 2. Syntheses and antitumor activities of 1-(tetrahydro-2-furanyl)-5-fluorouracil and 1,3-bis(tetrahydro-2-furanyl)-5-fluorouracil. |
| AID1146943 | Antitumor activity against rat AH-130 cells allografted in Donryu rat assessed as tumor inhibition at 0.45 mmol/kg, po qd for 7 days measured on day 10 relative to control | 1978 | Journal of medicinal chemistry, Aug, Volume: 21, Issue:8 | Studies on antitumor agents, 2. Syntheses and antitumor activities of 1-(tetrahydro-2-furanyl)-5-fluorouracil and 1,3-bis(tetrahydro-2-furanyl)-5-fluorouracil. |
| AID1146949 | Toxicity in Donryu rat allografted with rat AH-130 cells assessed as body weight change at 0.45 mmol/kg, po administered for 7 days measured on day 10 relative to control | 1978 | Journal of medicinal chemistry, Aug, Volume: 21, Issue:8 | Studies on antitumor agents, 2. Syntheses and antitumor activities of 1-(tetrahydro-2-furanyl)-5-fluorouracil and 1,3-bis(tetrahydro-2-furanyl)-5-fluorouracil. |
| AID1146948 | Toxicity in Donryu rat allografted with rat AH-130 cells assessed as body weight change at 0.15 mmol/kg, po administered for 7 days measured on day 10 relative to control | 1978 | Journal of medicinal chemistry, Aug, Volume: 21, Issue:8 | Studies on antitumor agents, 2. Syntheses and antitumor activities of 1-(tetrahydro-2-furanyl)-5-fluorouracil and 1,3-bis(tetrahydro-2-furanyl)-5-fluorouracil. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 9 (69.23) | 18.7374 |
| 1990's | 4 (30.77) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.
| This Compound (110.52) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 1 (6.25%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 15 (93.75%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||